98%
921
2 minutes
20
Recent changes in the aetiology and epidemiology of invasive candidiasis have serious implications for current and future diagnosis, treatment and prognosis. The aim of the current review was to discuss the epidemiology of invasive candidiasis, the distribution of Candida species in different regions of the world, the medical concerns of the changing aetiology and the emergence of antifungal resistance. Overall burden of invasive candidiasis remains high, especially in vulnerable persons, such as the elderly, immunosuppressed or debilitated patients. Moreover, there is a progressive shift in the aetiology of invasive candidiasis from Candida albicans to other species of Candida, probably related to the increased use of azole drugs with a clear trend towards increased antifungal resistance. Finally, the emergence and rise of multiresistant species, such as Candida auris or Candida glabrata, is a major threat making necessary invasive candidiasis worldwide surveillances. These changes have serious implications for the diagnosis, treatment and prognosis of invasive candidiasis. Updated knowledge of the current local epidemiology of invasive candidiasis is critical for the clinical management.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10123-018-0014-1 | DOI Listing |
J Infect Dev Ctries
August 2025
Hospital Infection Control Committee, Adana City Training and Research Hospital, Adana, Türkiye.
Introduction: Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes.
View Article and Find Full Text PDFCurr Opin Crit Care
October 2025
Department of Health Sciences (DISSAL), University of Genoa.
Purpose Of Review: In candidemia, the standard 14-day antifungal treatment after blood culture clearance has been long accepted, despite being based on limited and outdated evidence. This review discusses the rationale for re-evaluating treatment duration, in the context of growing interest in optimizing antifungal use.
Recent Findings: A small number of retrospective studies have explored shorter treatment courses in uncomplicated candidemia, suggesting similar outcomes in terms of mortality and recurrence compared to the traditional 14-day regimen.
Objectives: (formerly ) is a leading cause of invasive candidiasis and rapidly develops antifungal drug resistance during treatment. An increasing number of clinical isolates shows reduced susceptibility to echinocandins and azoles, leaving amphotericin B (AMB) as a last therapeutic option. Resistance of to this drug is rare and its underlying mechanisms are still not fully understood.
View Article and Find Full Text PDFmSystems
September 2025
Department of Microbiology, Faculty of Science, University of Manitoba, Winnipeg, Manitoba, Canada.
Unlabelled: Vulvovaginal candidiasis is a very common human fungal infection. Most are successfully treated with antifungal drugs, yet ~8% lead to recurrent vulvovaginal candidiasis (RVVC). Vaginal and rectal populations have been previously found to be closely related in RVVC.
View Article and Find Full Text PDFMicrobiol Spectr
September 2025
Institute of Medical Technology, Peking University Health Science Center, Beijing, China.
To evaluate the diagnostic performance of the 1,3-β-D-glucan (BDG) test and the galactomannan (GM) antigen test in invasive fungal infections (IFI) among hematologic patients and to explore an optimized diagnostic approach. A total of 294 consecutive patients with hematological diseases suspected of fungal infections were enrolled at Peking University People's Hospital from January 2020 to October 2023. IFI diagnosis referred to a composite reference standard (CRS), which combined both mycological and clinical evidence.
View Article and Find Full Text PDF